Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis.

Sofianopoulou E, Kaptoge S, Gräf S, Hadinnapola C, Treacy CM, Church C, Coghlan G, Gibbs JSR, Haimel M, Howard LS, Johnson M, Kiely DG, Lawrie A, Lordan J, MacKenzie Ross RV, Martin JM, Moledina S, Newnham M, Peacock AJ, Price LC, Rhodes CJ, Suntharalingam J, Swietlik EM, Toshner MR, Wharton J, Wilkins MR, Wort SJ, Pepke-Zaba J, Condliffe R, Corris PA, Di Angelantonio E, Provencher S, Morrell NW.

Eur Respir J. 2019 May 30;53(5). pii: 1801429. doi: 10.1183/13993003.01429-2018. Print 2019 May.

PMID:
30923185
2.

ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.

Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ.

Eur Respir J. 2019 Feb 28;53(2). pii: 1800332. doi: 10.1183/13993003.00332-2018. Print 2019 Feb.

PMID:
30578391
3.

Pulmonary hypertension in chronic lung disease and hypoxia.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.

4.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

5.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

6.

Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.

Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, Dewey FE, Overton JD, Reid JG, Shuldiner AR, Baras A, Sampson KJ, Bleda M, Hadinnapola C, Haimel M, Bogaard HJ, Church C, Coghlan G, Corris PA, Eyries M, Gibbs JSR, Girerd B, Houweling AC, Humbert M, Guignabert C, Kiely DG, Lawrie A, MacKenzie Ross RV, Martin JM, Montani D, Peacock AJ, Pepke-Zaba J, Soubrier F, Suntharalingam J, Toshner M, Treacy CM, Trembath RC, Vonk Noordegraaf A, Wharton J, Wilkins MR, Wort SJ, Yates K, Gräf S, Morrell NW, Krishnan U, Rosenzweig EB, Shen Y, Nichols CG, Kass RS, Chung WK.

Circ Genom Precis Med. 2018 Oct;11(10):e002087. doi: 10.1161/CIRCGEN.118.002087.

7.

Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England.

Martinez C, Wallenhorst C, Teal S, Cohen AT, Peacock AJ.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018791358. doi: 10.1177/2045894018791358. Epub 2018 Jul 9.

8.

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension.

Brash L, Barnes GD, Brewis MJ, Church AC, Gibbs SJ, Howard LSGE, Jayasekera G, Johnson MK, McGlinchey N, Onorato J, Simpson J, Stirrat C, Thomson S, Watson G, Wilkins MR, Xu C, Welsh DJ, Newby DE, Peacock AJ.

JACC Basic Transl Sci. 2018 Mar 28;3(2):176-186. doi: 10.1016/j.jacbts.2018.01.013. eCollection 2018 Apr.

9.

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Gräf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, Hodgson J, Liu B, Salmon RM, Southwood M, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Aldred M, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, MacKenzie Ross RV, Moledina S, Montani D, Newnham M, Olschewski A, Olschewski H, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Stein DF, Suntharalingam J, Swietlik EM, Toshner MR, van Heel DA, Vonk Noordegraaf A, Waisfisz Q, Wharton J, Wort SJ, Ouwehand WH, Soranzo N, Lawrie A, Upton PD, Wilkins MR, Trembath RC, Morrell NW.

Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.

10.

Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension.

Pellino K, Kerridge S, Church C, Peacock AJ, Crowe T, Jayasekera G, Johnson MK, MacKenzie AM.

Eur Respir J. 2018 Jan 31;51(2). pii: 1700444. doi: 10.1183/13993003.00444-2017. Print 2018 Feb.

11.

Non-invasive imaging of global and regional cardiac function in pulmonary hypertension.

Crowe T, Jayasekera G, Peacock AJ.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217742000. doi: 10.1177/2045893217742000. Epub 2017 Oct 24.

12.

A novel single-beat approach to assess right ventricular systolic function.

Bellofiore A, Vanderpool R, Brewis MJ, Peacock AJ, Chesler NC.

J Appl Physiol (1985). 2018 Feb 1;124(2):283-290. doi: 10.1152/japplphysiol.00258.2017. Epub 2017 Oct 12.

13.

A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension.

Panagiotou M, Johnson MK, Louvaris Z, Baker JS, Church AC, Peacock AJ, Vogiatzis I.

J Appl Physiol (1985). 2017 Oct 1;123(4):851-859. doi: 10.1152/japplphysiol.00986.2016. Epub 2017 Jun 29.

14.

Measuring the effects of treatment in patients with PAH: should we image the right ventricle?

Peacock AJ.

Eur Respir J. 2017 Jun 29;49(6). pii: 1700805. doi: 10.1183/13993003.00805-2017. Print 2017 Jun. No abstract available.

15.

Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival.

Blyth KG, Bellofiore A, Jayasekera G, Foster JE, Steedman T, Chesler NC, Peacock AJ.

Pulm Circ. 2017 Apr-Jun;7(2):465-475. doi: 10.1177/2045893217704838. Epub 2017 Mar 27.

16.

Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.

Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland.

J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014. Epub 2016 Dec 31.

PMID:
28190786
17.

Validation of impedance cardiography in pulmonary arterial hypertension.

Panagiotou M, Vogiatzis I, Jayasekera G, Louvaris Z, Mackenzie A, Mcglinchey N, Baker JS, Church AC, Peacock AJ, Johnson MK.

Clin Physiol Funct Imaging. 2018 Mar;38(2):254-260. doi: 10.1111/cpf.12408. Epub 2017 Feb 6.

PMID:
28168802
18.

Pulmonary vascular and cardiac impairment in interstitial lung disease.

Panagiotou M, Church AC, Johnson MK, Peacock AJ.

Eur Respir Rev. 2017 Jan 17;26(143). pii: 160053. doi: 10.1183/16000617.0053-2016. Print 2017 Jan. Review.

19.

Dynamic near-infrared spectroscopy assessment as an important tool to explore pulmonary arterial hypertension pathophysiology.

Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, McKenzie A, Mcglinchey N, Baker JS, Church AC, Peacock AJ, Johnson MK.

Eur Respir J. 2017 Jan 4;49(1). pii: 1602161. doi: 10.1183/13993003.02161-2016. Print 2017 Jan. No abstract available.

20.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

21.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Gräf S, Morrell NW, Wilkins MR.

Circulation. 2017 Jan 31;135(5):460-475. doi: 10.1161/CIRCULATIONAHA.116.024602. Epub 2016 Nov 21.

22.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
23.

Near infrared spectroscopy for the assessment of peripheral tissue oxygenation in pulmonary arterial hypertension.

Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, MacKenzie A, Mcglinchey N, Baker JS, Church AC, Peacock AJ, Johnson MK.

Eur Respir J. 2016 Oct;48(4):1224-1227. doi: 10.1183/13993003.01022-2016. Epub 2016 Sep 1. No abstract available.

24.

Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.

Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N.

J Heart Lung Transplant. 2017 Apr;36(4):399-406. doi: 10.1016/j.healun.2016.04.013. Epub 2016 May 6.

PMID:
27282418
25.

Imaging right ventricular function to predict outcome in pulmonary arterial hypertension.

Brewis MJ, Bellofiore A, Vanderpool RR, Chesler NC, Johnson MK, Naeije R, Peacock AJ.

Int J Cardiol. 2016 Sep 1;218:206-211. doi: 10.1016/j.ijcard.2016.05.015. Epub 2016 May 13.

26.

Imaging the heart in pulmonary hypertension: an update.

Grünig E, Peacock AJ.

Eur Respir Rev. 2015 Dec;24(138):653-64. doi: 10.1183/16000617.0058-2015. Review.

27.

Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Panagiotou M, Peacock AJ, Johnson MK.

Pulm Circ. 2015 Sep;5(3):424-34. doi: 10.1086/682431. Review.

28.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

29.

Severe pulmonary hypertension in lung disease: phenotypes and response to treatment.

Brewis MJ, Church AC, Johnson MK, Peacock AJ.

Eur Respir J. 2015 Nov;46(5):1378-89. doi: 10.1183/13993003.02307-2014. Epub 2015 Aug 20.

30.

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA.

J Heart Lung Transplant. 2015 Nov;34(11):1366-75. doi: 10.1016/j.healun.2015.05.025. Epub 2015 Jun 11.

31.

Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.

Peacock AJ, Zamboni W, Vizza CD.

Curr Med Res Opin. 2015;31(9):1793-807. doi: 10.1185/03007995.2015.1074890. Epub 2015 Aug 27. Review.

PMID:
26196225
32.

Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

MacKenzie AM, Peacock AJ.

Curr Hypertens Rep. 2015 Jul;17(7):56. doi: 10.1007/s11906-015-0560-2. Review.

PMID:
26068652
33.

The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension.

Church AC, Martin DH, Wadsworth R, Bryson G, Fisher AJ, Welsh DJ, Peacock AJ.

Am J Physiol Lung Cell Mol Physiol. 2015 Aug 15;309(4):L333-47. doi: 10.1152/ajplung.00038.2015. Epub 2015 May 29.

34.

[Pulmonary arterial hypertension: epidemiology and registries].

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:67-77. Turkish.

35.

Pulmonary hypertension in POEMS syndrome: resolution following radiotherapy.

Brewis MJ, Church AC, Peacock AJ, Thomson S, Tighe J, Johnson MK.

Pulm Circ. 2014 Dec;4(4):732-5. doi: 10.1086/678553.

36.

Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt?

McGlinchey N, Peacock AJ.

Drug Discov Today. 2014 Aug;19(8):1236-40. doi: 10.1016/j.drudis.2014.04.020. Epub 2014 May 9. Review.

PMID:
24814434
37.

Pulmonary arterial hypertension: epidemiology and registries.

McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023. Review.

38.

Cardiac magnetic resonance imaging in pulmonary arterial hypertension.

Peacock AJ, Vonk Noordegraaf A.

Eur Respir Rev. 2013 Dec;22(130):526-34. doi: 10.1183/09059180.00006313. Review.

39.

Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.

Peacock AJ, Crawley S, McLure L, Blyth KG, Vizza CD, Poscia R, Francone M, Iacucci I, Olschewski H, Kovacs G, Vonk Noordegraaf A, Marcus JT, van de Veerdonk MC, Oosterveer FP.

Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14. doi: 10.1161/CIRCIMAGING.113.000629. Epub 2013 Oct 30. Erratum in: Circ Cardiovasc Imaging. 2017 Feb;10 (2):.

PMID:
24173272
40.

LA volume by CMR distinguishes idiopathic from pulmonary hypertension due to HFpEF.

Crawley SF, Johnson MK, Dargie HJ, Peacock AJ.

JACC Cardiovasc Imaging. 2013 Oct;6(10):1120-1121. doi: 10.1016/j.jcmg.2013.05.014. No abstract available.

41.

Cellular responses to hypoxia in the pulmonary circulation.

Welsh DJ, Peacock AJ.

High Alt Med Biol. 2013 Jun;14(2):111-6. doi: 10.1089/ham.2013.1016. Review.

PMID:
23795730
42.

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA.

Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12.

PMID:
23403476
43.

Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel.

Burns RM, Peacock AJ, Johnson MK, Church AC.

Respir Med. 2013 Feb;107(2):298-304. doi: 10.1016/j.rmed.2012.10.007. Epub 2012 Nov 3.

44.

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, Howard LS, Pepke-Zaba J, Sheares KK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA, Peacock AJ.

Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6. doi: 10.1164/rccm.201203-0383OC. Epub 2012 Jul 12.

PMID:
22798320
45.

Predicting survival in pulmonary arterial hypertension in the UK.

Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK.

Eur Respir J. 2012 Sep;40(3):604-11. doi: 10.1183/09031936.00196611. Epub 2012 May 3.

46.

Quantitative estimation of right ventricular hypertrophy using ECG criteria in patients with pulmonary hypertension: A comparison with cardiac MRI.

Blyth KG, Kinsella J, Hakacova N, McLure LE, Siddiqui AM, Wagner GS, Peacock AJ.

Pulm Circ. 2011 Oct-Dec;1(4):470-4. doi: 10.4103/2045-8932.93546.

47.

Low-dose fluvastatin reverses the hypoxic pulmonary adventitial fibroblast phenotype in experimental pulmonary hypertension.

Carlin CM, Celnik DF, Pak O, Wadsworth R, Peacock AJ, Welsh DJ.

Am J Respir Cell Mol Biol. 2012 Aug;47(2):140-8. doi: 10.1165/rcmb.2011-0411OC. Epub 2012 Mar 1.

PMID:
22383583
48.

Use of non-invasive haemodynamic measurements to detect treatment response in precapillary pulmonary hypertension.

Lee WT, Brown A, Peacock AJ, Johnson MK.

Thorax. 2011 Sep;66(9):810-4. doi: 10.1136/thx.2011.159228. Epub 2011 Jun 23.

PMID:
21700759
49.

Survival in pulmonary hypertension registries: the importance of incident cases.

Condliffe R, Kiely DG, Coghlan JG, Gibbs JSR, Wort SJ, Corris PA, Peacock AJ, Pepke-Zaba J; Adult Pulmonary Hypertension Service of the United Kingdom.

Chest. 2011 Jun;139(6):1547-1548. doi: 10.1378/chest.10-3348. No abstract available.

PMID:
21652570
50.

Non-invasive stroke volume measurement by cardiac magnetic resonance imaging and inert gas rebreathing in pulmonary hypertension.

McLure LE, Brown A, Lee WN, Church AC, Peacock AJ, Johnson MK.

Clin Physiol Funct Imaging. 2011 May;31(3):221-6. doi: 10.1111/j.1475-097X.2010.01004.x. Epub 2011 Jan 7.

PMID:
21470362

Supplemental Content

Loading ...
Support Center